Document is current

Article History

Accepted: 28 October 2024

First Online: 29 November 2024

Declarations

:

: None.

: Dr Jensen Yeung has been an advisor, consultant, speaker, and/or investigator for AbbVie, Amgen, Anacor, Arcutis, Astellas, Bausche, Baxalta, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Centocor, Coherus, Dermira, Forward, Fresenius Kabi, Galderma, Incyte, Janssen, LEO Pharma, Medimmune, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi Genzyme, Sun Pharma, Takeda, UCB, and Xenon. Dr Jensen Yeung is an Editorial Board member of the American Journal of Clinical Dermatology. He was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Mr Sood has no relevant disclosures.

: IRB approval was obtained by the research ethics boards at each respective academic institution from which data was collected (Sunnybrook Health Sciences Centre [205-2018]; Women’s College Hospital [2018-0079-E]).

: Requirements for patient consent were waived for this study due to the use of anonymized and deidentified data.

: Requirements for patient consent were waived for this study due to the use of anonymized and deidentified data.

: Supplementary data is available via Mendeley at ()

: Not applicable.

: JY contributed to study conceptualization, methods, data collection, and manuscript preparation. SS contributed to data analysis and manuscript preparation.